Screener
Charles River Laboratories CRL RMS — Acquisitions
Other segment segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Charles River Laboratories in its filing.
Tagged under the XBRL concept us-gaap:GoodwillAcquiredDuringPeriod.
The source filing: Charles River Laboratories’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 9:21 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001100682-26-000118
| Line item | RMS | DSA (1) | Manufacturing (2) | Total |
|---|---|---|---|---|
| December 27, 2025 | $510,844 | $1,678,518 | $574,891 | $2,764,253 |
| Acquisitions | — | 335,906 | 39,786 | 375,692 |
| Divestitures | — | (37,701) | — | (37,701) |
| Foreign exchange | (551) | (19,320) | (5,522) | (25,393) |
| June 27, 2026 | $510,293 | $1,957,403 | $609,155 | $3,076,851 |
| (1) DSA includes accumulated impairment losses of $1 billion, which were recognized in fiscal years 2008 and 2010. | ||||
| (2) Manufacturing includes accumulated impairment losses of $380 million, which were recognized in fiscal years 2024 and 2025. |
Item 1. Financial Statements
FAQ
- What is Charles River Laboratories's RMS — acquisitions?
- Charles River Laboratories (CRL) reported RMS — acquisitions of $0 in Q2 2026.
- What does RMS — acquisitions mean?
- Measures the total cash or consideration paid by the Research Models and Services segment to acquire other businesses or assets. This metric is a primary indicator of the segment's inorganic growth strategy and capital deployment priorities. It tracks the scale of expansion through external purchases rather than organic development.
Ask your AI about Charles River Laboratories's rms — acquisitions.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude